XML 15 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. STOCK-BASED COMPENSATION
6 Months Ended
Nov. 30, 2019
Share-based Payment Arrangement [Abstract]  
12. STOCK-BASED COMPENSATION

12. STOCK-BASED COMPENSATION

 

    Stock-based compensation expense consists of expenses for stock options, restricted stock units, or RSUs, and employee stock purchase plan, or ESPP, purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs, stock-based compensation cost is based on the fair value of the Company’s common stock at the grant date. All of the Company’s stock-based compensation is accounted for as an equity instrument. See Note 10 in the Company’s Annual Report on Form 10-K for fiscal 2019 filed on August 28, 2019 for further information regarding the 2016 Equity Incentive Plan and the Amended and Restated 2006 ESPP.

 

    The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2019 and 2018 (in thousands):

 

   Three Months Ended  Six Months Ended
   November 30,  November 30,
   2019  2018  2019  2018
Stock-based compensation in the form of employee stock options, RSUs and
ESPP purchase rights, included in:
            
Cost of sales  $19   $23   $39   $59 
Selling, general and administrative   135    136    264    284 
Research and development   51    65    101    137 
Total stock-based compensation  $205   $224   $404   $480 

 

    As of November 30, 2019 and 2018, there were no stock-based compensation expenses capitalized as part of inventory.

 

    During the three months ended November 30, 2019 and 2018, the Company recorded stock-based compensation expense related to stock options and RSUs of $163,000 and $166,000, respectively. During the six months ended November 30, 2019 and 2018, the Company recorded stock-based compensation expense related to stock options and RSUs of $313,000 and $339,000, respectively.

 

    As of November 30, 2019, the total compensation expense related to unvested stock-based awards under the Company’s 2016 Equity Incentive Plan, but not yet recognized, was approximately $1,405,000, which is net of estimated forfeitures of $4,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 3.0 years.

 

    During the three months ended November 30, 2019 and 2018, the Company recorded stock-based compensation expense related to the ESPP of $42,000 and $58,000, respectively. During the six months ended November 30, 2019 and 2018, the Company recorded stock-based compensation expense related to the ESPP of $91,000 and $141,000, respectively.

 

    As of November 30, 2019, the total compensation expense related to purchase rights under the ESPP but not yet recognized was approximately $117,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 0.9 years.

 

Valuation Assumptions

 

    Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

    Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

 

    Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility for the past four or five years, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

 

    Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

 

    Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2019 and 2018 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:

 

   Three Months Ended  Six Months Ended
   November 30,  November 30,
   2019  2018  2019  2018
             
Expected term (in years)   5    5    5    5 
Volatility   0.72    0.70    0.71    0.72 
Risk-free interest rate   1.60%    3.01%    1.85%    2.84% 
Weighted average grant date fair value  $1.05   $1.21   $0.98   $1.38 

 

   The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2019 were estimated using the following weighted-average assumptions:

 

   Three and Six Months Ended
   November 30, 2019
    
Expected term (in years)   0.5-2.0 
Volatility   0.62-0.71 
Expected dividend  $0.00 
Risk-free interest rates   1.56% - 1.81% 
Estimated forfeiture rate   0% 
Weighted average grant date fair value  $0.80 

 

    During the three and six months ended November 30, 2019, ESPP purchase rights of 38,000 were granted. During the three and six months ended November 30, 2018, ESPP purchase rights of 327,000 were granted. Total ESPP shares issued during the three and six months ended November 30, 2019 and 2018 were 71,000 and 64,000 shares, respectively. As of November 30, 2019, there were 299,000 ESPP shares available for issuance.

 

    The following tables summarize the Company’s stock option and RSU transactions during three and six months ended November 30, 2019 (in thousands):

 

   Available
   Shares
Balance, May 31, 2019   1,147 
      
  Options granted   (527)
  Options cancelled   151 
  Options expired   (119)
      
Balance, August 31, 2019   652 
      
  Options reserved   1,196 
  Options granted   (58)
  Options cancelled   280 
  Options expired   (256)
      
Balance, November 30, 2019   1,814 

 

    The following table summarizes the stock option transactions during the three and six months ended November 30, 2019 (in thousands, except per share data):

 

    Outstanding Options 
         Weighted      
    Number    Average    Aggregate 
    of    Exercise    Intrinsic 
    Shares    Price    Value 
Balances, May 31, 2019   3,107   $2.20   $282 
                
Options granted   527   $1.64      
Options cancelled   (151)  $1.50      
Options exercised   (49)  $1.27      
                
Balances, August 31, 2019   3,434   $2.16   $41 
                
Options granted   58   $1.77      
Options cancelled   (280)  $2.19      
Options exercised   (85)  $1.06      
                
Balances, November 30, 2019  $3,127   $2.18   $358 
                
Options fully vested and expected to vest at November 30, 2019  $3,091   $2.18   $354 

 

    The options outstanding and exercisable at November 30, 2019 were in the following exercise price ranges (in thousands, except per share data):

 

   Options Outstanding  Options Exercisable
   at November 30, 2019  at November 30, 2019

Range of
Exercise Prices

  Number Outstanding Shares  Weighted Average Remaining Contractual Life (Years)  Weighted Average Exercise Price  Number Exercisable Shares  Weighted Average Remaining Contractual Life (Years)  Weighted Average Exercise Price  Aggregate Intrinsic Value
1.09-$1.28    260    0.57   $1.28    260    0.57   $1.28      
1.64-$2.06    1,199    5.53   $1.76    447    4.22   $1.81      
2.10-$2.81    1,439    3.13   $2.43    1,146    2.48   $2.43      
3.46-$3.93    229    4.66   $3.85    151    4.69   $3.80      
1.09-$3.93    3,127    3.95   $2.18    2,004    2.79   $2.25   $219 

 

    The total intrinsic value of options exercised during the three and six months ended November 30, 2019 was $50,000 and $67,000, respectively. The total intrinsic value of options exercised during the three and six months ended November 30, 2018 was $23,000 and $162,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2019 was 3.93 years.

 

    There were no RSUs granted to employees during the three and six months ended November 30, 2019 and 2018. During the three and six months ended November 30, 2019, 3,000 and 7,000 RSUs became fully vested, respectively. During the three and six months ended November 30, 2018, 4,000 and 9,000 RSUs became fully vested, respectively. As of November 30, 2019, 16,000 RSUs were unvested which had an intrinsic value of $31,000. As of November 30, 2018, 38,000 RSUs were unvested which had an intrinsic value of $72,000.